PRME primemedicine.com: Enterprise Value to EBITDA Ratio
Prime Medicine, Inc. (PRME) is a biotech pioneer developing a precision DNA editing method that avoids helix breaks to correct genetic defects. This daily chart from GURU.Markets based on the Enterprise Value to EBITDA multiple demonstrates that the indicator stands at 0.00. Prime Medicine, Inc. (PRME) acts as a global innovator investing in the fight against severe pathologies, while its laboratories operate stably thanks to the automation of nucleic acid synthesis.
primemedicine.com - analytical breakdowns and key metrics (PRME)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Prime Medicine, Inc.|PRME - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Prime Medicine|PRME - Company Total Debt Obligations|Debts to Book Capitalization Prime Medicine Bio|PRME - Company Long-Term Liabilities|Company Short-Term Debts Prime Medicine|Quick Liquidity primemedicine.com
- business earnings and investment ratios data:
PRME - Company Profit|Projected Future Earnings Prime Medicine, Inc.|PRME - Market Cap to Earnings|Projected Price to Earnings Prime Medicine, Inc.|PRME - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Prime Medicine Bio|PRME - Operating income before deduction of amortization|Earnings per share for the last twelve months Prime Medicine|PRME - Earnings per share for the last 12 months|Quarterly EPS earnings growth primemedicine.com|PRME - Net earnings per share growth this year|Expected earnings per share growth for next year Prime Medicine, Inc.
- sales and revenue data:
Comprehensive company analysis:Prime Medicine Corp PRME
To objectively assess asset value, it is essential for investors to analyze the ratio of total enterprise value to operating profit before depreciation and interest. By examining the historical EV/EBITDA chart for Prime Medicine, Inc. (PRME), one can determine the real value of the enterprise while accounting for debt load, which is critical for Prime Medicine, Inc. (PRME) given its maintenance of a costly network of specialized laboratories and the management of complex logistics for genetic drugs.
Competitors of Prime Medicine, Inc. (PRME)
EV/EBITDA Multiple TEM (tempus.com)|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CRISPR Therapeutics Inc|WGS (Sema4) - EV/EBITDA Multiple|Company Value to EBITDA Ultragenyx Corp RARE|EV/EBITDA Multiple BEAM|sarepta.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS: EV/EBITDA Multiple|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Enterprise Value to Operating Income Before Depreciation SION (Sionna Therapeutics, Inc.)|EV/EBITDA Multiple TSHA|QURE - Company Value to EBITDA|MeiraGTx Holdings plc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGNX|Solid Biosciences - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ocugen Inc OCGN|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BNTC|DSGN (Design Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio rocketpharma.com (RCKT)|Enterprise Value to EBITDA Ratio FDMT (4D Molecular Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT (Editas Corp) - Company Value to Operating Income Before Depreciation Ratio|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PRQR (ProQR Therapeutics N.V.)|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Sangamo Therapeutics Inc.|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Metagenomi Therapeutics MGX|EV/EBITDA Multiple DTIL|generationbio.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|XCUR: Enterprise Value to Operating Income Before Depreciation|Celsion Corporation - EV/EBITDA Multiple|PHIO - EV/EBITDA Multiple|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RNAZ (TransCode Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|APDN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC - Enterprise Value to EBITDA Ratio|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Company Value to EBITDA Syros Pharmaceuticals Inc.|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TRACON Pharmaceuticals, Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
